Search
SEC News ARCHIVE

Early Version of Cancer Genome Reveals Vital Vulnerabilities

In a collaborative effort across a number of institutions, including Harvard, the Dana-Farber Cancer Institute, and the Broad Institute of MIT, researchers have narrowed down 760 genes directly responsible for the survival of cancer cells.

Rachel Kowalski
Rachel KowalskiCybersecurity Analyst
2 min read
Early Version of Cancer Genome Reveals Vital Vulnerabilities

In a collaborative effort across a number of institutions, including Harvard, the Dana-Farber Cancer Institute, and the Broad Institute of MIT, researchers have narrowed down 760 genes directly responsible for the survival of cancer cells.

Although most of the vulnerable genes vary from one cancer type to another, around 10 percent are consistent between types, making them possible targets for cancer-fighting therapies.

The study, published in the journal Cell, utilized small interfering RNA, or siRNA, to turn off single lines of DNA and see which cells were affected. Overall, 17,000 genes were tested in over 20 different kinds of cancer.

Even though so many genes were studied, 90 percent of the cancers tested only vitally relied on 76 sets of genes, indicating that many other cancers may also have a small core of key genes that can be exploited as treatment targets.

Working with genome-wide cancer “dependency map” (inset below) Broad Institute researchers identified 760 genes that cancer cells need for their growth and survival. Broad Institute

Additionally, a scientist used biomarkers to divide cells into groups that describe their role in biology with over 400 of the 769 mapped genes.The groups account for roles such as gene mutation, reduced or increased gene expression, and gene function.

Through the study, it was discovered that 20 percent of the vital genes were already targeted for existing drug therapies, providing more proof of their efficacy.

While the full cancer genome hasn’t been identified for all types, the work is well under way, meaning doctors and scientists have more information with which to battle cancer and help patients with better treatments.

More News to Read

Related Coverage

Google · Preferred Sources

Don't miss new tech stories on Google

Add TrendinTech once in the Google app and our stories appear in your news suggestions.

Add Now
Rachel Kowalski

Rachel Kowalski

Cybersecurity Analyst

Rachel Kowalski is the Cybersecurity Analyst at TrendinTech, where she covers vulnerabilities, ransomware, supply chain attacks, nation-state operations and the security rules shaping organizations in the United States and Europe. Before moving into journalism she worked as a threat intelligence analyst at a security vendor and later reported for CyberScoop and the security desk at Wired, covering the SolarWinds compromise and the ransomware wave that hit hospitals and pipelines. Rachel holds a Master of Science in Cybersecurity from the Georgia Institute of Technology and attends Black Hat and DEF CON in Las Vegas each year, where she follows research from the security community. She writes to make risks and countermeasures understandable to people who are not specialists.

All stories by Rachel Kowalski (214)